FDA re­jects Check­point Ther­a­peu­tic­s' PD-L1 drug cosi­be­limab over man­u­fac­tur­ing is­sues

Check­point Ther­a­peu­tics’ an­ti-PD-L1 an­ti­body has been turned down by the FDA due to man­u­fac­tur­ing is­sues, send­ing its share price down 45% pre­mar­ket on Mon­day. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER